<?xml version='1.0' encoding='utf-8'?>
<document id="23748441"><sentence text="Effect of netupitant, a highly selective NKâ‚ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives."><entity charOffset="93-105" id="DDI-PubMed.23748441.s1.e0" text="palonosetron" /><entity charOffset="150-160" id="DDI-PubMed.23748441.s1.e1" text="netupitant" /><entity charOffset="165-177" id="DDI-PubMed.23748441.s1.e2" text="palonosetron" /><entity charOffset="203-215" id="DDI-PubMed.23748441.s1.e3" text="ketoconazole" /><entity charOffset="217-227" id="DDI-PubMed.23748441.s1.e4" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e0" e2="DDI-PubMed.23748441.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e0" e2="DDI-PubMed.23748441.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e0" e2="DDI-PubMed.23748441.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e0" e2="DDI-PubMed.23748441.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e0" e2="DDI-PubMed.23748441.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e1" e2="DDI-PubMed.23748441.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e1" e2="DDI-PubMed.23748441.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e1" e2="DDI-PubMed.23748441.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e1" e2="DDI-PubMed.23748441.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e2" e2="DDI-PubMed.23748441.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e2" e2="DDI-PubMed.23748441.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e2" e2="DDI-PubMed.23748441.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e3" e2="DDI-PubMed.23748441.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s1.e3" e2="DDI-PubMed.23748441.s1.e4" /></sentence><sentence text="Neurokinin-1 receptor antagonists (NK1 RAs) are commonly coadministered with a 5-HT3 RA such as palonosetron to prevent nausea and vomiting induced by chemotherapy"><entity charOffset="96-108" id="DDI-PubMed.23748441.s2.e0" text="palonosetron" /></sentence><sentence text=" Netupitant, a new highly selective NK1 RA, is both a substrate for and a moderate inhibitor of CYP3A4" /><sentence text=" Three studies were designed to evaluate the potential drug-drug interaction of netupitant with palonosetron and of the fixed dose combination of netupitant and palonosetron, NEPA, with an inhibitor (ketoconazole), an inducer (rifampicin) and a substrate (oral contraceptives) of CYP3A4"><entity charOffset="96-108" id="DDI-PubMed.23748441.s4.e0" text="palonosetron" /><entity charOffset="146-156" id="DDI-PubMed.23748441.s4.e1" text="netupitant" /><entity charOffset="161-173" id="DDI-PubMed.23748441.s4.e2" text="palonosetron" /><entity charOffset="175-179" id="DDI-PubMed.23748441.s4.e3" text="NEPA" /><entity charOffset="200-212" id="DDI-PubMed.23748441.s4.e4" text="ketoconazole" /><entity charOffset="227-237" id="DDI-PubMed.23748441.s4.e5" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e0" e2="DDI-PubMed.23748441.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e1" e2="DDI-PubMed.23748441.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e1" e2="DDI-PubMed.23748441.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e1" e2="DDI-PubMed.23748441.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e1" e2="DDI-PubMed.23748441.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e1" e2="DDI-PubMed.23748441.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e2" e2="DDI-PubMed.23748441.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e2" e2="DDI-PubMed.23748441.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e2" e2="DDI-PubMed.23748441.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e2" e2="DDI-PubMed.23748441.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e3" e2="DDI-PubMed.23748441.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e3" e2="DDI-PubMed.23748441.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e3" e2="DDI-PubMed.23748441.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e4" e2="DDI-PubMed.23748441.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23748441.s4.e4" e2="DDI-PubMed.23748441.s4.e5" /></sentence><sentence text="" /><sentence text="Study 1 was a three-way crossover in 18 healthy subjects receiving netupitant alone, palonosetron alone, and the combination of both antiemetics"><entity charOffset="85-97" id="DDI-PubMed.23748441.s6.e0" text="palonosetron" /></sentence><sentence text=" Studies 2 and 3 were two-way crossover trials where healthy subjects received NEPA (the fixed dose combination of netupitant and palonosetron)"><entity charOffset="115-125" id="DDI-PubMed.23748441.s7.e0" text="netupitant" /><entity charOffset="130-142" id="DDI-PubMed.23748441.s7.e1" text="palonosetron" /><entity charOffset="79-90" id="DDI-PubMed.23748441.s7.e2" text="NEPA" /><pair ddi="false" e1="DDI-PubMed.23748441.s7.e2" e2="DDI-PubMed.23748441.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s7.e2" e2="DDI-PubMed.23748441.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s7.e2" e2="DDI-PubMed.23748441.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s7.e0" e2="DDI-PubMed.23748441.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s7.e0" e2="DDI-PubMed.23748441.s7.e1" /></sentence><sentence text=" In study 2, 36 subjects received NEPA alone (day 1) and in combination with ketoconazole or rifampicin"><entity charOffset="77-89" id="DDI-PubMed.23748441.s8.e0" text="ketoconazole" /><entity charOffset="93-103" id="DDI-PubMed.23748441.s8.e1" text="rifampicin" /><entity charOffset="34-43" id="DDI-PubMed.23748441.s8.e2" text="NEPA" /><pair ddi="false" e1="DDI-PubMed.23748441.s8.e2" e2="DDI-PubMed.23748441.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s8.e2" e2="DDI-PubMed.23748441.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s8.e2" e2="DDI-PubMed.23748441.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s8.e0" e2="DDI-PubMed.23748441.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s8.e0" e2="DDI-PubMed.23748441.s8.e1" /></sentence><sentence text=" In study 3, 24 healthy women received ethinylestradiol/levonorgestrel alone or in combination with NEPA (day 1)"><entity charOffset="39-55" id="DDI-PubMed.23748441.s9.e0" text="ethinylestradiol" /><entity charOffset="56-70" id="DDI-PubMed.23748441.s9.e1" text="levonorgestrel" /><entity charOffset="100-104" id="DDI-PubMed.23748441.s9.e2" text="NEPA" /><pair ddi="false" e1="DDI-PubMed.23748441.s9.e0" e2="DDI-PubMed.23748441.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s9.e0" e2="DDI-PubMed.23748441.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s9.e0" e2="DDI-PubMed.23748441.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s9.e1" e2="DDI-PubMed.23748441.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s9.e1" e2="DDI-PubMed.23748441.s9.e2" /></sentence><sentence text="" /><sentence text="There were no significant pharmacokinetic interactions between netupitant and palonosetron"><entity charOffset="78-90" id="DDI-PubMed.23748441.s11.e0" text="palonosetron" /></sentence><sentence text=" Ketoconazole increased netupitant area under curve (AUC) by 140 % and C max by 25 %"><entity charOffset="1-13" id="DDI-PubMed.23748441.s12.e0" text="Ketoconazole" /></sentence><sentence text=" Rifampicin decreased netupitant AUC by 83 % and C max by 62 %"><entity charOffset="1-11" id="DDI-PubMed.23748441.s13.e0" text="Rifampicin" /></sentence><sentence text=" NEPA did not significantly affect exposure to ethinylestradiol, while systemic exposure to levonorgestrel increased by 40 %, but this was not considered clinically relevant"><entity charOffset="47-63" id="DDI-PubMed.23748441.s14.e0" text="ethinylestradiol" /><entity charOffset="92-106" id="DDI-PubMed.23748441.s14.e1" text="levonorgestrel" /><entity charOffset="1-14" id="DDI-PubMed.23748441.s14.e2" text="NEPA" /><pair ddi="false" e1="DDI-PubMed.23748441.s14.e2" e2="DDI-PubMed.23748441.s14.e2" /><pair ddi="false" e1="DDI-PubMed.23748441.s14.e2" e2="DDI-PubMed.23748441.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s14.e2" e2="DDI-PubMed.23748441.s14.e1" /><pair ddi="false" e1="DDI-PubMed.23748441.s14.e0" e2="DDI-PubMed.23748441.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s14.e0" e2="DDI-PubMed.23748441.s14.e1" /></sentence><sentence text="" /><sentence text="There were no clinically relevant interactions between netupitant and palonosetron, or between NEPA and oral contraceptives"><entity charOffset="70-82" id="DDI-PubMed.23748441.s16.e0" text="palonosetron" /><entity charOffset="95-106" id="DDI-PubMed.23748441.s16.e1" text="NEPA" /><pair ddi="false" e1="DDI-PubMed.23748441.s16.e0" e2="DDI-PubMed.23748441.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23748441.s16.e0" e2="DDI-PubMed.23748441.s16.e1" /></sentence><sentence text=" The coadministration of NEPA with inhibitors or inducers of CYP3A4 may require dose adjustments"><entity charOffset="25-28" id="DDI-PubMed.23748441.s17.e0" text="NEPA" /></sentence><sentence text=" Treatments were well tolerated" /><sentence text="" /></document>